Home > Gastroenterology > ECCO 2018 > IBD disease patterns and genetics > Integration of “omics” and potential for clinical practice

Integration of “omics” and potential for clinical practice

ECCO 2018

“Omics” have accelerated drug discovery for clinical practice and are therefore promising elements in optimising IBD treatment [22]. They can be used for each of the four basic components in IBD pathogenesis (see Table).

Table: Basic components of IBD and their treatment strategies [24]


Omics-based biomarkers for clinical practice are able to detect subtypes (molecular signatures). Thus, they suit a holistic view of the patient integrating the person, the affected organ, its lesion, as well as cell and molecular structures [23,34].

  1. Kralyevic S, et al. EMBO Rep. 2004;5:837-42.
  2. Stylianou DE. Mol Diagn Ther. 2018;22:11-23.
  3. Fiocchi C, et al. ECCO 20...

    Please login to read the full text of the article.

    If you have no account yet, please register now.

    Posted on